MX2009013341A - Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina. - Google Patents

Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina.

Info

Publication number
MX2009013341A
MX2009013341A MX2009013341A MX2009013341A MX2009013341A MX 2009013341 A MX2009013341 A MX 2009013341A MX 2009013341 A MX2009013341 A MX 2009013341A MX 2009013341 A MX2009013341 A MX 2009013341A MX 2009013341 A MX2009013341 A MX 2009013341A
Authority
MX
Mexico
Prior art keywords
sup
pyrrolopyridinyl
pyrimidine
amine derivatives
compounds
Prior art date
Application number
MX2009013341A
Other languages
English (en)
Spanish (es)
Inventor
Dieter Dorsch
Christian Sirrenberg
Lars Thore Burgdorf
Christina Esdar
Thomas J J Mueller
Eugen Merkul
Margarita Wuchrer
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2009013341A publication Critical patent/MX2009013341A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2009013341A 2007-06-21 2008-05-23 Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina. MX2009013341A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007028515A DE102007028515A1 (de) 2007-06-21 2007-06-21 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
PCT/EP2008/004151 WO2008155000A1 (de) 2007-06-21 2008-05-23 6-(pyrrolopyridinyl)- pyrimidin-2-yl-amin-derivate und ihre verwendung zur behandlung von krebs und aids

Publications (1)

Publication Number Publication Date
MX2009013341A true MX2009013341A (es) 2010-01-18

Family

ID=39916277

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013341A MX2009013341A (es) 2007-06-21 2008-05-23 Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina.

Country Status (16)

Country Link
US (1) US8546390B2 (enExample)
EP (1) EP2155745B1 (enExample)
JP (1) JP5411849B2 (enExample)
KR (1) KR20100040862A (enExample)
CN (1) CN101679425B (enExample)
AR (1) AR067081A1 (enExample)
AU (1) AU2008266584B2 (enExample)
BR (1) BRPI0812944A2 (enExample)
CA (1) CA2691223C (enExample)
DE (1) DE102007028515A1 (enExample)
EA (1) EA016160B1 (enExample)
ES (1) ES2533873T3 (enExample)
IL (1) IL202828A0 (enExample)
MX (1) MX2009013341A (enExample)
WO (1) WO2008155000A1 (enExample)
ZA (1) ZA201000432B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2078020A4 (en) * 2007-04-10 2011-10-19 Sgx Pharmaceuticals Inc HETEROCYCLIC MODULATORS WITH FUSED CYCLES FOR KINASES
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
DE102009019962A1 (de) * 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
DE102009060174A1 (de) 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
DE102009060175A1 (de) 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen
DE102010050558A1 (de) * 2010-11-05 2012-05-10 Merck Patent Gmbh 1H-Pyrrolo[2,3-b]pyridinderivate
DE102010053347A1 (de) * 2010-12-03 2012-06-06 Merck Patent Gmbh 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
DE102011009961A1 (de) 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
CN105732639A (zh) 2012-06-29 2016-07-06 辉瑞大药厂 作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
TWI498325B (zh) * 2013-01-18 2015-09-01 Hoffmann La Roche ３－取代吡唑及其用途
JP6325078B2 (ja) * 2013-03-15 2018-05-16 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． ヘテロ環式化合物およびその使用
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
WO2017161004A1 (en) 2016-03-15 2017-09-21 University Of South Florida PKCδ INHIBITOR FORMULATIONS AND USES THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS
CA3017388C (en) 2016-04-01 2024-03-12 Zeno Royalties & Milestones, LLC Estrogen receptor modulators
EP3694855A1 (en) 2017-10-13 2020-08-19 Plexxikon Inc. Solid forms of a compound for modulating kinases
CN113710668B (zh) * 2019-04-09 2025-01-07 Opna生物公司 用于ep300或cbp调节及其适应症的缩合吖嗪
US11278532B2 (en) 2019-08-06 2022-03-22 Recurium Ip Holdings, Llc Estrogen receptor modulators for treating mutants
CN118772140A (zh) * 2023-04-07 2024-10-15 四川大学 一类化合物及其在治疗hDHODH介导的疾病中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
US6265434B1 (en) 1999-04-06 2001-07-24 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
NZ584499A (en) * 2004-03-30 2011-08-26 Vertex Pharma Azaindoles Useful as Inhibitors of Jak and Other Protein Kinases
WO2005123672A2 (en) * 2004-06-14 2005-12-29 Takeda San Diego, Inc. Kinase inhibitors
US7361763B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US20090233955A1 (en) * 2004-12-08 2009-09-17 Frazee James S 1H-Pyrrolo[2,3-B]Pyridnes
AU2006247322A1 (en) * 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
DE102006012617A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate

Also Published As

Publication number Publication date
JP5411849B2 (ja) 2014-02-12
KR20100040862A (ko) 2010-04-21
US8546390B2 (en) 2013-10-01
ZA201000432B (en) 2010-10-27
BRPI0812944A2 (pt) 2014-12-16
EA201000004A1 (ru) 2010-06-30
EP2155745B1 (de) 2015-01-28
JP2010530376A (ja) 2010-09-09
WO2008155000A1 (de) 2008-12-24
AU2008266584B2 (en) 2013-04-04
CA2691223C (en) 2015-12-01
CN101679425B (zh) 2013-11-06
AU2008266584A1 (en) 2008-12-24
CA2691223A1 (en) 2008-12-24
ES2533873T3 (es) 2015-04-15
EP2155745A1 (de) 2010-02-24
DE102007028515A1 (de) 2008-12-24
US20110082140A1 (en) 2011-04-07
IL202828A0 (en) 2010-06-30
AR067081A1 (es) 2009-09-30
CN101679425A (zh) 2010-03-24
EA016160B1 (ru) 2012-02-28

Similar Documents

Publication Publication Date Title
MX2009013341A (es) Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina.
WO2010000364A8 (de) Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
MX2010003366A (es) Derivados de piperidina y piperazina para el tratamiento de tumores.
MX2013008212A (es) Derivados de 7-azaindol.
MX2009013077A (es) Derivados dde benzoxazolona.
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
MX2009012708A (es) Derivados de piridazinona.
MX352975B (es) Piridina y derivados de pirazina.
MX2010003368A (es) Derivados de imidazol.
MX2009010034A (es) Pirimidodiazepinas sustituidas utiles inhibidores de la plk1.
MX2013004491A (es) Boronatos como inhibidores de arginasa.
MX340714B (es) Inhibidores de hsp90.
EP2170337A4 (en) NEW TRIAZOLOPYRIDAZINE
MX2009001309A (es) Compuestos de heteroarilo utiles como inhibidores de enzimas de activacion e1.
MX2014002683A (es) Derivados de benzonitrilo como inhibidores de cinasa.
MX2012000711A (es) Inhibidores de pirrolopirazina de cinasas.
MX2011011488A (es) Derivados de 3-([1,2,3]triazol-4-il)-pirrolo[2,3-b]piridina.
MX2014003376A (es) Derivados de acido benzoico como inhibidores eif4e.
MX2010007927A (es) Derivados de 4-(pirrolo[2,3-c]piridin-3-il)pirimidin-2-ilamina.
MX2009012709A (es) Derivados de arileter-piridazinona.
TW200745004A (en) Novel compounds, their preparation and use
MX349550B (es) 1,7-diazacarbazoles y metodos de uso.
MX336022B (es) Activadores de pkm2 bicíclicos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal